

AMENDMENT TO THE CLAIMS


Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims:

1. (Currently amended) A drug delivery ophthalmic lens comprising a cationic group-containing drug in the inside of a copolymer, wherein the copolymer consists of: ~~consisting~~ ~~consists of~~

(a) a hydrophilic monomer having a hydroxyl group in its ~~molecule;~~ ~~molecule,~~


(b) at least one ~~member-selected from~~ phosphate group-containing methacrylate ~~methacrylates~~ represented by the following structural formula (I) ~~formula (I);~~



(I);

(c) a monomer having a nitrogen atom in its side ~~chain;~~ ~~chain,~~ and



(d) a monomer copolymerizable with (a), (b) and (c). ~~these components;~~



formulae (I).

2. (Original) The drug delivery ophthalmic lens according to claim 1, wherein a mixture of the following structural formulae (II) and (III) is used as the phosphate group-containing

methacrylates:



3. (original) The drug delivery ophthalmic lens according to claim 1, wherein the content of the monomer having a nitrogen atom in its side chain is 0.05 to 40 wt %.
4. (original) The drug delivery ophthalmic lens according to claim 1, wherein the monomer having a nitrogen atom in its side chain is (meth)acrylamide.
5. (original) The drug delivery ophthalmic lens according to claim 1, wherein the cationic group-containing drug is an organic compound having at least one quaternary ammonium base or primary to tertiary amine base in its molecule.
6. (original) A drug delivery ophthalmic lens comprising an anionic group-containing drug in the inside of a copolymer consisting of a hydrophilic monomer, cationic and anionic monomers, and a monomer copolymerizable with these components, wherein the copolymer contains the anionic monomer in a ratio of 30 to 90 mol % to the cationic monomer.
7. (original) The drug delivery ophthalmic lens according to claim 6, wherein the anionic group-containing drug is an organic compound having at least one member selected from a carboxyl group, a sulfo group and a phosphate group in its molecule.

8. (original) A solution for storing the drug delivery ophthalmic lens according to claim 6, which comprises a nonionic surfactant and a nonionic osmotic pressure regulating agent and is free of an ionic compound.
9. (currently amended) The storing solution according to claim 8, wherein the nonionic surfactant is a polyoxyethylene/polyoxypropylene nonionic surfactant (poloxamer type) and the nonionic osmotic pressure regulating agent is propylene glycol or glycerin.
10. (currently amended) The storing solution according to claim 8, wherein the solution has a pH between 5.0 to 7.5; the amount of non-ionic surfactant is present in an amount up to 0.5% by weight and the nonionic osmotic pressure regulating agent is present in an amount up to 4% by weight. ~~nonionic osmotic pressure regulating agent is propylene glycol or glycerin.~~
11. (new) The drug delivery ophthalmic lens of claim 6, wherein the copolymer contains the anionic monomer in a ratio of 40 to 80 mol % to the cationic monomer.
12. (new) The drug delivery ophthalmic lens of claim 11, wherein the anionic group-containing drug is water-soluble azulene.
13. (new) The drug delivery ophthalmic lens according to claim 2, wherein the content of the monomer having a nitrogen atom in its side chain is 0.05 to 40 wt %.
14. (new) The drug delivery ophthalmic lens according to claim 13, wherein the monomer having a nitrogen atom in its side chain is (meth)acrylamide.
15. (new) The drug delivery ophthalmic lens according to claim 14, wherein the cationic group-containing drug is an organic compound having at least one quaternary ammonium base or primary to tertiary amine base in its molecule.
16. (new) The drug delivery ophthalmic lens according to claim 13, wherein the total amount of the monomers of structural formulae (II) and (III) is 0.5 to 20 wt.% based on the amount of

monomers in total, and the amount of the compound of the structural formula (II) is 75 to 85 wt. % based on the total amount of the monomers of the structural formulae (II) and (III).

17. (new) The drug delivery ophthalmic lens according to claim 16, wherein the amount of the cationic monomer is in the range of 2 to 50 mol. % relative to the hydrophilic monomer.

18. (new) The drug delivery ophthalmic lens according to claim 17, wherein the cationic group-containing drug is naphazoline nitrate.